The FDA's Pharmacy Compounding Advisory Committee on July 23 and 24 recommended six peptides for the agency's 503A Bulks List, splitting from the agency's own career scientists on every compound under review. BPC-157, KPV, and TB-500 each passed 8 to 6 with one abstention; MOTS-c cleared 7 to 5. Semax followed at 8 to 5 and epitalon at 7 to 4 on the second day. Emideltide, the sole rejection, fell 6 to 7. FDA staff had recommended against all seven, as reported by the American Journal of Managed Care.
The vote is a recommendation, not a rule. Placement on the 503A Bulks List would let licensed compounding pharmacies prepare these peptides against individual prescriptions, but that authority does not exist until the FDA completes notice-and-comment rulemaking. Scott Brunner, CEO of the Alliance for Pharmacy Compounding, stated that the agency must formally adopt the advisers' recommendations before any of the six may be legally compounded. None carries FDA drug approval.
Staff objections and a chemical-identity problem
Figure 1: Regulatory framework and distribution compliance overview for FDA Panel's Narrow Vote Leaves BPC-157 and Semax in Regulatory Limbo.
FDA reviewers told the committee that available evidence, including five BPC-157 trials, was short in duration, small in sample size, and insufficient to establish safety or effectiveness for the reviewed indications. Russell Wesdyk, an FDA official addressing the panel on the first morning, identified a more basic obstacle: the agency could not confirm a universally accepted chemical identity for several of the compounds under evaluation, according to PharmExec's coverage of the July 23 session.
The staff applied the four-part test codified at 21 CFR 216.23(c)—physical and chemical characterization, historical compounding use, evidence of effectiveness, and safety—and reached the same conclusion for each peptide: do not add it to the list. The panel disagreed on six of seven.
Dr. Brian Lee, an associate professor at the Keck School of Medicine of USC who voted no, told the committee the endorsement "can be potentially harmful" absent adequate human evidence. Elizabeth Rebello, an anesthesiologist at MD Anderson Cancer Center, also dissented.
Panel composition drew conflict-of-interest scrutiny
The committee that cast these votes was reconstituted before the meeting. Eight members were appointed under the current administration; six of them operate clinics that offer peptide therapies. Reporting by the Associated Press, cited by NBC News, identified at least seven members with financial ties to the peptide industry. On the first day's BPC-157, KPV, and TB-500 votes, all eight new appointees voted yes.
David Pope, chief pharmacy officer at Xifin Pharmacy Solutions in Georgia, framed his yes vote as returning the decision "to the hands of the patient, the physician and the pharmacist." Dr. Gabriel Alizaidy, a clinical researcher at the online clinic Maximus, voted for BPC-157 while acknowledging he was "frankly disappointed at how incomplete the data was."
The agency reviewed each peptide for a narrow indication—BPC-157 for ulcerative colitis, TB-500 and KPV for wound healing, MOTS-c for obesity and osteoporosis, Semax for cerebral ischemia and migraine, epitalon for insomnia. Once a substance reaches the 503A list, however, clinicians retain prescribing discretion beyond those reviewed uses. That gap was raised during the meeting but not resolved by the vote.
Rulemaking has no published timeline
The grey-market peptides sold online under "research use only" labels continue to operate outside pharmaceutical quality controls, and the PCAC vote does not alter enforcement posture. HHS Secretary Robert F. Kennedy Jr., who has called himself "a big fan" of peptides, could seek to expedite the rulemaking, though experts say the mechanics remain unclear. NPR reported the formal process could stretch into next year or 2028.
Historical precedent supports patience. The rule establishing the current 503A list took effect in February 2019. A further tranche of five substances proposed in September 2019 still lacks a final rule. Glutathione, which received a favorable PCAC vote in June 2022, has not made the list, according to a regulatory timeline tracked by Peptides Insider.
The FDA has not published a proposed rule or announced a timeline for one. The next scheduled PCAC session, confirmed for before the end of February 2027, will review GHK-Cu, LL-37, Dihexa acetate, Melanotan II, and PEG-MGF. BPC-157 and Semax will not appear on that agenda. Their status remains a recommendation on file, pending an agency decision that no one has dated.
Related Peptides Agora coverage examines are peptides legal.
